Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes

Back

ESC Professional Premium Access

Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes

Session: Post-myocardial infarction management

Topic: Antidiabetic Pharmacotherapy

Speaker: Associate Professor M. Cavender (Chapel Hill, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Associate Professor Matthew Cavender

University of North Carolina Hospitals, Chapel Hill (United States of America)

6 presentations

0 follower

5 more presentations in this session

Beta-blockers improved cardiovascular outcome in AMI patients with severe heart failure: a multi-center real-world study

Speaker: Doctor R. Guo (Tianjin, CN)

Beta-blocker duration and long-term cardiovascular risk after myocardial infarction with reduced ejection fraction

Speaker: Doctor S. Fang (Bristol, GB)

Antithrombotic therapy in patients with takotsubo cardiomyopathy: is heparin associated with lower mortality? - a nationwide cohort analysis

Speaker: Doctor S. Hijikata (Tokyo, JP)

Proton pump inhibitors in myocardial infarction: safety paradox in Type 1 vs. Type 2---a multicenter retrospective cohort study

Speaker: Doctor J. Ren (Tianjin, CN)

Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial

Speaker: Professor M. Shechter (Ramat Gan, IL)

Access the full session

Post-myocardial infarction management

Speakers: Associate Professor M. Cavender, Doctor R. Guo, Doctor S. Fang, Doctor S. Hijikata, Doctor J. Ren...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources